Vera Therapeutics (VERA) Cash & Equivalents (2020 - 2026)

Vera Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $114.4 million for Q1 2026.

• Quarterly Cash & Equivalents rose 107.57% year-over-year to $114.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $114.4 million (up 107.57% YoY) and the FY2025 annual result came in at $354.7 million, up 282.88% from the prior year.
• Cash & Equivalents was $114.4 million for Q1 2026 at Vera Therapeutics, down from $354.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $354.7 million in Q4 2025 and bottomed at $25.1 million in Q2 2024.
• A 5-year average of $78.0 million and a median of $50.4 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 64.64% — and 2025, when it jumped 282.88%.
• Vera Therapeutics' Cash & Equivalents stood at $43.5 million in 2022, then advanced by 5.11% to $45.7 million in 2023, then surged by 102.81% to $92.6 million in 2024, then soared by 282.88% to $354.7 million in 2025, then tumbled by 67.76% to $114.4 million in 2026.
• Business Quant data shows VERA's Cash & Equivalents at $114.4 million in Q1 2026, $354.7 million in Q4 2025, and $57.8 million in Q3 2025.